TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7574856
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 20 mg once daily
Study: 1058542
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times repeated spray application
Study: 1058542
Drug: Antiseptics added
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptics added to the spray
Study: 24997757
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol and gestodene patch (delivering low doses equivalent to 0.02 mg EE and 0.06 mg GSD) applied once weekly for 3 weeks
Study: 24997757
Drug: CYP3A4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4 inhibitors (erythromycin and ketoconazole) administered concurrently with the patch
Study: 24997757
Drug: Midazolam (CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (CYP3A4 substrate) administered alone and after 3 weeks of concurrent patch application
Study: 23351464
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention and optimal medical therapy
Study: 15089890
Drug: Licofelone 200
Normalized name: Licofelone
DrugBank: Licofelone (DB04725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone 200 mg b.i.d. (n = 30)
Study: 15089890
Drug: Licofelone 400
Normalized name: Licofelone
DrugBank: Licofelone (DB04725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone 400 mg b.i.d. (n = 30)
Study: 15089890
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg b.i.d. (n = 30)
Study: 15089890
Drug: Licofelone 200
Normalized name: Licofelone
DrugBank: Licofelone (DB04725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone 200 mg b.i.d.
Study: 15089890
Drug: Licofelone 400
Normalized name: Licofelone
DrugBank: Licofelone (DB04725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone 400 mg b.i.d.
Study: 15089890
Drug: Licofelone 200
Normalized name: Licofelone
DrugBank: Licofelone (DB04725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone 200 mg b.i.d. or Naproxen therapy
Study: 15089890
Drug: Licofelone or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone or Naproxen therapy
Study: 11455257
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2 mg/kg per day
Study: 17460145
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1 g twice daily
Study: 9726387
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., clarithromycin 250 mg b.d.)
Study: 9726387
Drug: LAM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Study: 9726387
Drug: LCM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Study: 8070443
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 mg/kg/day)
Study: 8070443
Drug: Ketoconazole (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (7 mg/kg/day)
Study: 20510523
Drug: High exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exposure group (≥500 mg/week)
Study: 20510523
Drug: Moderate exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exposure group (250-499 mg/week)
Study: 20510523
Drug: Zero-low exposure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zero-low exposure group (0-249 mg/week)
Study: 11372922
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (Botox) injections via percutaneous posterior‐lateral approach
Study: 11372922
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (Botox) injections via transnasal fiberoptic approach
Study: 9425975
Drug: L2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L2 group (injection at the second lumbar vertebra)
Study: 9425975
Drug: L4 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L4 group (injection at the fourth lumbar vertebra)
Study: 8276982
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen daily for 14 days in 4 divided doses
Study: 8276982
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug regime (control group)
Study: 31879077
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (20-g protein-rich supplement)
Study: 31879077
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (20-g calorie-matched carbohydrate-rich supplement)
Study: 30700175
Drug: GnRHa 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET)
Study: 28100402
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant and inhaled nitric oxide
Study: 28100402
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide alone (control)
Study: 9150838
Drug: Inhaled amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amiloride
Study: 29862617
Drug: Trelagliptin 100
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin 100 mg with insulin (A/A group)
Study: 29862617
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with insulin (P/A group)
Study: 26887502
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 55 mg BTP
Study: 23241332
Drug: Dance group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance group (n = 15) - cognitive-motor exercise program with dance video gaming, 12 weeks, twice weekly.
Study: 23241332
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 16) - strength and balance exercises only, 12 weeks, twice weekly.
Study: 18515185
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine 1 mg over 24 h (n=115)
Study: 18515185
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine 2 mg over 24 h (n=112)
Study: 18515185
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine 3 mg over 24 h (n=114)
Study: 15696321
Drug: Caffeine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.2 mg/kg) after 8 hours of abstinence
Study: 15696321
Drug: Caffeine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.2 mg/kg) after 4 hours of abstinence
Study: 386118
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day)
Study: 386118
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (closely regulated)
Study: 386118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiplatelet or anticoagulant therapy)
Study: 11211903
Drug: Propranolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (30 mg, administered orally once daily at 19:00 h for 14 days)
Study: 11211903
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered orally once daily at 19:00 h for 14 days)
Study: 7927544
Drug: REmbIZ3 (rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: REmbIZ3 (rifampicin, ethambutol, isoniazid, pyrazinamide together in a single dose thrice weekly)
Study: 2671282
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy and adjuvant doxorubicin and cyclophosphamide chemotherapy
Study: 2671282
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy and chemotherapy
Study: 793778
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg suloctidil t.i.d.
Study: 793778
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg dihydroergotoxine methylate t.i.d.
Study: 28475201
Drug: Sensor-based balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-based balance training (4 weeks, twice a week) with real-time visual/audio feedback from wearable sensors.
Study: 19834348
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (SUPP) - 400 mg caffeine, 66.7 mg capsicum extract, 10 mg bioperine, 40 mg niacin
Study: 16096896
Drug: IV ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ampicillin (100 mg/kg/day divided every 6 h)
Study: 16096896
Drug: IV ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ampicillin plus IV gentamicin (5 mg/kg as a single daily dose)
Study: 10713874
Drug: Dimenhydrinate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (1 mg kg‐1)
Study: 10713874
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol (15 micrograms kg‐1) + dimenhydrinate (1 mg kg‐1)
Study: 10713874
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups compared to placebo
Study: 7555612
Drug: L-lysine-L-arginine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine-L-arginine combination (lisargin)
Study: 7335762
Drug: Indobufen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (200 mg b.i.d. by oral route)
Study: 30794364
Drug: Natural regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural regimen (NR) consisting of a cleanser with natural oils, beeswax, and witch hazel, and day and night creams with natural oils, glycerin, and botanical anti-inflammatories.
Study: 30794364
Drug: Synthetic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic regimen (CR) consisting of a cetyl alcohol, sodium lauryl sulphate-containing cleanser, and glycerin, polyisobutene-containing lotion.
Study: 25011730
Drug: computerised CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: computerised CBT (cCBT) using OCFighter, an internet-delivered OCD treatment package
Study: 22362228
Drug: Mesoglycan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (100 mg/day for 6 months)
Study: 20976505
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection speed (mean 0.38 ml/s)
Study: 20976505
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection speed (0.05 ml/s over 40 s)
Study: 20976505
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection speed
Study: 20976505
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection speed
Study: 16774821
Drug: Salbutamol (S,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with volume-controlled (VC) ventilation
Study: 16774821
Drug: Salbutamol (S,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with pressure-support (PS) ventilation
Study: 12730756
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily (Once-a-Week study)
Study: 15465985
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior treatment of residual symptoms (supplemented by lifestyle modification and well-being therapy)
Study: 11176319
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days
Study: 11176319
Drug: Placebo (nonimmunized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nonimmunized chicken preparation)
Study: 10626096
Drug: mianserin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 15 mg/d for 3 weeks
Study: 7589820
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with sulfonylurea or insulin
Study: 7589820
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy primarily with diet
Study: 7589820
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with metformin
Study: 7589820
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy compared with conventional therapy
Study: 1770147
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n = 33) using transvaginal methotrexate or sulprostone injection
Study: 23585468
Drug: Cognitive‐behavioral psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral psychotherapy combined with intramuscular (IM) 3‐monthly injections of triptorelin for 12 months (total of 4 injections)
Study: 23585468
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with cognitive‐behavioral psychotherapy for 12 months (total of 4 injections)
Study: 18277375
Drug: 1 L/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group A
Study: 18277375
Drug: 1 L/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group B1
Study: 18277375
Drug: 1 L/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/d placebo mineral water (Ca:80 mg/L) for Group B2
Study: 18277375
Drug: 1 L/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group B2 (after switching from placebo)
Study: 1468826
Drug: Enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-20 mg per day
Study: 6504945
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg twice daily
Study: 6504945
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg twice daily
Study: 6504945
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of pivmecillinam
Study: 30940355
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration injections
Study: 27454274
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 0.5 mg/kg
Study: 27454274
Drug: Caudal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Caudal dexamethasone 0.1 mg/kg
Study: 9199122
Drug: Program III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program III - Expanded educational activity and professional cleaning of teeth, sealing, and intensive conservative treatment
Study: 8293692
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin 75 mg/day (study group, n = 40)
Study: 23609777
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (daily oral Zn supplements for two months)
Study: 19543667
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for warmth therapy
Study: 16936149
Drug: Intravenous C‐peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C‐peptide infusion (dosage 1: 25 pmol . kg(‐1) . min(‐1) bolus followed by 5 pmol . kg(‐1) . min(‐1) continuous infusion; dosage 2: six times higher than dosage 1)
Study: 16936149
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution (control)
Study: 15238460
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 12 months
Study: 11182002
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with vinorelbine, paclitaxel, or gemcitabine plus cisplatin followed by concomitant chemoradiotherapy with the same agents and standard radiation (66 Gy)
Study: 10221358
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (CMI) 50-200 mg daily
Study: 8032080
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine spray (Groups A and C)
Study: 2480941
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600 cGy or 800 cGy
Study: 2480941
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose therapy
Study: 4866185
Drug: Pyridoxine 6
Normalized name: GLYCINE 750MG/NIACIN 25MG/PYRIDOXINE 6MG PWDR,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 6 mg daily
Study: 4866185
Drug: Pyridoxine 6
Normalized name: GLYCINE 750MG/NIACIN 25MG/PYRIDOXINE 6MG PWDR,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 6 mg or 48 mg
Study: 4866185
Drug: High-dosage isoniazid
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage isoniazid
Study: 22933750
Drug: Boiled white-fleshed
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule
Study: 22933750
Drug: Boiled orange-fleshed
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Study: 22933750
Drug: Fried orange-fleshed
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Study: 22933750
Drug: Boiled white-fleshed
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled white-fleshed sweet potatoes (WFSP) and a retinyl palmitate capsule
Study: 20505660
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg modafinil (divided into three doses)
Study: 12843214
Drug: SPECT imaging
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT imaging after intravenous injection of hexamethylpropyleneamine oxime or ethylcysteinate dimer
Study: 2223528
Drug: Diuretic (half-strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (half-strength Moduretic: hydrochlorothiazide 25 mg + amiloride hydrochloride 2.5 mg)
Study: 2223528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol, hydrochlorothiazide, and amiloride hydrochloride
Study: 2223528
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (atenolol or diuretic)
Study: 80275
Drug: Adriamycin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (60 mg/m2 every 3 weeks)
Study: 80275
Drug: Bleomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (15 mg/m2 weekly)
Study: 21060109
Drug: IDX184 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 5 mg
Study: 21060109
Drug: IDX184 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 10 mg
Study: 21060109
Drug: IDX184 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 25 mg
Study: 21060109
Drug: IDX184 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg
Study: 21060109
Drug: IDX184 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 75 mg
Study: 21060109
Drug: IDX184 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 100 mg
Study: 19597358
Drug: Self‐Focused Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐Focused Exposure Therapy
Study: 17313720
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation at 15 mg/d for 6 months
Study: 17313720
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation at 30 mg/d for 6 months
Study: 15108100
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B oral suspension
Study: 15108100
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral suspension
Study: 7861714
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day s.c. of recombinant human growth hormone (rhGH) during the treatment period
Study: 393464
Drug: fenbufen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenbufen (800 mg/day)
Study: 23679192
Drug: Toremifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 120 mg (TOR120)